Effects of the selective nonpeptide corticotropin-releasing factor receptor 1
antagonist antalarmin in the chronic mild stress model of depression in mice
by
Ducottet C, Griebel G, Belzung C.
EA 3248 Psychobiologie des emotions,
IFR120 Imagerie et exploration fonctionnelles,
Faculte des Sciences and Techniques,
UFR Sciences et techniques,
Universite Francois Rabelais,
Parc de Grandmont Avenue Monge,
F-37200, Tours, France.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):625-31

ABSTRACT

Several recent studies on corticotropin-releasing factor (CRF) have suggested that this neuropeptide may play a role in depression. Consequently, CRF receptor antagonists have been proposed as potential new agents for the treatment of this condition. This study investigated the effects of a 4-week treatment with the well-known CRF(1) receptor antagonist, antalarmin, and the prototypical selective serotonin reuptake inhibitor (SSRI), fluoxetine, in the chronic mild stress (CMS) model in BALB/c mice. Animals were exposed to 9 weeks of CMS which rapidly (within 2 weeks) produced decrease of physical state (PS), body weight gain and blunted emotional response in the light/dark test. Chronic treatment with antalarmin (10 mg/kg ip) and fluoxetine (10 mg/kg ip) led to an improvement of CMS-induced modifications. These results suggest that CRF(1) receptor antagonists may represent potential antidepressants.

CRF
LHPA
Astressin
Antalarmin
Ketoconazole
Noradrenaline
Corticosteroids
Cushing's syndrome
Glucocorticoids and mood
Hippocampal remodelling
CRF-1 receptor antagonists
HPA axis, serotonin and suicide
Depression, opioids and the HPA
Antidepressants and new brain cells
The corticosteroid hypothesis of depression
An overactive immune system and depression

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family